Eli Lilly’s orforglipron received approval in China, placing it in competition with Novo Nordisk’s and Pfizer’s once-weekly GLP-1 injections and Innovent Biologics’ product. Lilly and Novo expect oral weight-loss drugs to attract patients reluctant to use injections. China’s National Health Commission has projected that more than 65% of the population could be overweight or obese by 2030.
Key facts
Pfizer’s once-weekly GLP-1 weight-loss injections are identified as competing in China with Eli Lilly’s orforglipron pill. source
Pfizer’s once-weekly GLP-1 injections are identified as competing with Eli Lilly’s weight-loss pill in China. source